MEDISWIPE, INC.
|
|
|
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30,
|
|
December 31,
|
|
|
2013
|
|
2012
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current Assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
116,887
|
|
|
$
|
1,892
|
|
Accounts receivable
|
|
|
31,653
|
|
|
|
14,133
|
|
Inventory
|
|
|
11,184
|
|
|
|
—
|
|
Deferred financing costs
|
|
|
21,787
|
|
|
|
2,203
|
|
Prepaid assets and other
|
|
|
3,050
|
|
|
|
—
|
|
Total current assets
|
|
$
|
184,561
|
|
|
$
|
18,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders' Deficiency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
146,987
|
|
|
$
|
99,130
|
|
Deferred compensation
|
|
|
3,000
|
|
|
|
40,880
|
|
Convertible debt, net of discounts of $50,150 (2013) and $19,648 (2012)
|
|
|
42,350
|
|
|
|
35,852
|
|
Convertible note payable (net of discount of $17,111)
|
|
|
210,389
|
|
|
|
—
|
|
Derivative liabilities
|
|
|
122,792
|
|
|
|
38,590
|
|
Litigation contingency
|
|
|
—
|
|
|
|
46,449
|
|
Total current liabilities
|
|
|
525,518
|
|
|
|
260,901
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Deficiency:
|
|
|
|
|
|
|
|
|
Series B convertible preferred stock, $0.01 par value; 1,000,000 shares authorized, 1,000,000 (2013) and
|
|
|
|
|
|
|
|
|
800,000 (2012) shares issued and outstanding
|
|
|
10,000
|
|
|
|
8,000
|
|
Common stock, $.01 par value; 500,000,000 shares authorized; 445,456,717 (2013) shares
|
|
|
|
|
|
|
|
|
and 466,632,164 (2012) shares issued and outstanding
|
|
|
4,454,569
|
|
|
|
4,666,324
|
|
Additional paid-in capital
|
|
|
3,714,104
|
|
|
|
202,372
|
|
Deferred stock compensation
|
|
|
(22,207
|
)
|
|
|
(222,083
|
)
|
Accumulated deficit
|
|
|
(8,497,423
|
)
|
|
|
(4,897,286
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders' deficiency
|
|
|
(340,957
|
)
|
|
|
(242,673
|
)
|
|
|
|
|
|
|
|
|
|
Total liabiities and stockholders' deficiency
|
|
$
|
184,561
|
|
|
$
|
18,228
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to condensed consolidated financial statements.
|
MEDISWIPE, INC.
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended June 30,
|
|
For the Six Months Ended June 30,
|
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fee revenue, net
|
|
$
|
—
|
|
|
$
|
23,334
|
|
|
$
|
49,818
|
|
|
$
|
49,458
|
|
Product revenue
|
|
|
38,267
|
|
|
|
|
|
|
|
38,267
|
|
|
|
|
|
Cost of sales product
|
|
|
24,369
|
|
|
|
—
|
|
|
|
24,369
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
13,898
|
|
|
|
23,334
|
|
|
|
63,716
|
|
|
|
49,458
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Administrative and management fees (including $3,072,264 and $3,116,681
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
stock based compensation for the three and six months ended June 30, 2013)
|
|
|
3,141,944
|
|
|
|
34,888
|
|
|
|
3,251,861
|
|
|
|
60,788
|
|
Professional and consulting fees (including $44,417 and $104,334 stock based
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
compensation for the three and six months ended June 30, 2013, respectively)
|
|
|
64,286
|
|
|
|
5,050
|
|
|
|
153,205
|
|
|
|
7,400
|
|
Commissions
|
|
|
—
|
|
|
|
—
|
|
|
|
31,200
|
|
|
|
8,512
|
|
Rent and other occupancy costs
|
|
|
15,031
|
|
|
|
5,957
|
|
|
|
18,783
|
|
|
|
11,683
|
|
Advertising and promotion
|
|
|
5,227
|
|
|
|
—
|
|
|
|
8,871
|
|
|
|
—
|
|
Other general and administrative expenses
|
|
|
21,029
|
|
|
|
21,209
|
|
|
|
47,080
|
|
|
|
33,043
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
3,247,517
|
|
|
|
67,104
|
|
|
|
3,511,000
|
|
|
|
121,426
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(3,233,619
|
)
|
|
|
(43,770
|
)
|
|
|
(3,447,284
|
)
|
|
|
(71,968
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(92,630
|
)
|
|
|
(46,812
|
)
|
|
|
(122,560
|
)
|
|
|
(92,936
|
)
|
Derivative liability (expense) income
|
|
|
(25,200
|
)
|
|
|
(26,668
|
)
|
|
|
(30,293
|
)
|
|
|
18,044
|
|
Gain on deconsolidation of subsidiary
|
|
|
—
|
|
|
|
62,636
|
|
|
|
—
|
|
|
|
62,636
|
|
Total other expense, net
|
|
|
(117,830
|
)
|
|
|
(10,844
|
)
|
|
|
(152,853
|
)
|
|
|
(12,256
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(3,351,449
|
)
|
|
|
(54,614
|
)
|
|
|
(3,600,137
|
)
|
|
|
(84,224
|
)
|
Less: net loss attributable to noncontrolling interest
|
|
|
—
|
|
|
|
413
|
|
|
|
—
|
|
|
|
695
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to Mediswipe, Inc.
|
|
$
|
(3,351,449
|
)
|
|
$
|
(54,201
|
)
|
|
$
|
(3,600,137
|
)
|
|
$
|
(83,529
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss attributable to Mediswipe, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
common stockholders, per share
|
|
$
|
(0.01
|
)
|
|
$
|
(0.00
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.00
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
473,220,659
|
|
|
|
395,033,751
|
|
|
|
469,983,005
|
|
|
|
394,982,232
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to condensed consolidated financial statements.
|
MEDISWIPE, INC
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
THE SIX MONTHS ENDED JUNE 30, 2013 AND 2012
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
2013
|
|
2012
|
CASH FLOWS FROM OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(3,600,137
|
)
|
|
$
|
(83,529
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Stock issued for consulting services
|
|
|
105,275
|
|
|
|
—
|
|
Amortization of deferred stock compensation
|
|
|
170,265
|
|
|
|
—
|
|
Preferred stock issued for services
|
|
|
2,821,275
|
|
|
|
—
|
|
Fair value of stock options issued
|
|
|
124,200
|
|
|
|
—
|
|
Amortization of deferred financing costs
|
|
|
13,916
|
|
|
|
5,546
|
|
Amortization of discounts on convertible notes
|
|
|
94,448
|
|
|
|
81,806
|
|
Change in fair market value of derivative liabilities
|
|
|
13,083
|
|
|
|
(19,755
|
)
|
Initial derivative liability expense on convertible notes
|
|
|
17,210
|
|
|
|
1,711
|
|
Change in noncontrolling interest
|
|
|
—
|
|
|
|
(695
|
)
|
Gain on deconsolidation of subsisiary
|
|
|
—
|
|
|
|
(62,636
|
)
|
Cash effect of deconsolidation
|
|
|
—
|
|
|
|
(5,166
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Increase in :
|
|
|
|
|
|
|
|
|
Inventory
|
|
|
(11,184
|
)
|
|
|
—
|
|
Accounts receivable
|
|
|
(17,520
|
)
|
|
|
(2,842
|
)
|
Prepaid assets and other
|
|
|
(3,050
|
)
|
|
|
—
|
|
Increase in :
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
|
58,572
|
|
|
|
10,983
|
|
Deferred compensation
|
|
|
62,142
|
|
|
|
45,000
|
|
Net cash used in operating activities
|
|
|
(151,505
|
)
|
|
|
(29,577
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt
|
|
|
92,500
|
|
|
|
32,500
|
|
Issuance of subsidiary common stock for cash
|
|
|
—
|
|
|
|
5,000
|
|
Proceeds from convertible notes
|
|
|
200,000
|
|
|
|
—
|
|
Payment of convertible notes
|
|
|
—
|
|
|
|
(8,000
|
)
|
Payment of deferred financing costs
|
|
|
(26,000
|
)
|
|
|
(2,500
|
)
|
Net cash provided by financing activities
|
|
|
266,500
|
|
|
|
27,000
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
114,995
|
|
|
|
(2,577
|
)
|
Cash and cash equivalents, beginning
|
|
|
1,892
|
|
|
|
3,355
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, ending
|
|
$
|
116,887
|
|
|
$
|
778
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
Schedule of non-cash financing activities:
|
|
|
|
|
|
|
|
|
Conversion of notes payable and interest into common stock
|
|
$
|
66,216
|
|
|
$
|
58,000
|
|
|
|
|
|
|
|
|
|
|
Settlement of accrued compensation with preferred stock
|
|
$
|
100,022
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
Conversion of litigation contingency liability into common stock
|
|
$
|
46,449
|
|
|
$
|
—
|
|
MEDISWIPE, INC.
NOTES TO UNAUDITED CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - ORGANIZATION
BUSINESS
MediSwipe Inc. (the
“Company” or “Mediswipe”) offers a complete line of merchant services providing innovative solutions
for electronically processing merchant and patient transactions within the healthcare industry. The Company is prim
arily
focused on providing innovative patient solutions to licensed medical marijuana dispensaries, pharmacies and healthcare
patient facilities.
Through
June 30, 2012, the Company provided merchant services to approximately forty medical dispensaries and wellness centers throughout
California and Colorado through our sponsor bank Electronic Merchant Systems (“EMS”). Effective July 1, 2012, EMS
advised all medical dispensaries that they will no longer accept their Visa and MasterCard transactions. This action had a materially
adverse effect on our business.
The
Company has utilized its existing banking and merchant network and moved toward vertical markets within both the medicinal medical
marijuana and healthcare sector over the last several months. During the three months ended March 31, 2013, through strategic
partnerships with banking and financing partners the Company received commission based fees for
arranging
for third party financing for elective surgery procedures
.
On
April 30, 2013 the Company entered into a one year Distribution Agreement with Chill Drinks, LLC (“Chill Drinks”).
Chill Drinks has the rights to an energy drink called Chillo Energy Drink (“Chillo”) and a hemp ice tea drink called
C+ Swiss Ice Tea (“C+Swiss”). Chillo and C+Swiss are referred to as the (“Chill Drink Products”). Pursuant
to the Distribution Agreement the Company has the exclusive distribution and placement rights of the Chill Drink Products to medical
dispensaries.
The
Company introduced during the quarter ending June 30, 2013, its’ proprietary
Data
Management System (DMS). DMS is designed specifically for medicinal dispensaries in regulated jurisdictions. The DMS application
is a HIPAA compliant, web-secure document repository and collaboration system, developed exclusively for
the
medical marijuana industry. DMS includes patient registration, digital records management and tracking of all caregiver transactions,
including log-in time, date stamp and quantity and type of medication prescribed. DMS was developed by industry leaders in
patient work-flow, and cloud-based web solutions to provide patients, caregivers, dispensaries, labs, providers and certification
centers with the industry's first complete, cloud-based network collaboration system.
The
patient records management system within DMS features include the importing, scanning, emailing and faxing of all medical records
and many other novel functions. DMS provides our users a manner to effectively manage their documents in one central, HIPAA compliant,
secure repository.
The
Company’s DMS's infrastructure is the only system available to the medical marijuana industry that allows patients, caregivers,
dispensaries, laboratories, providers and certification centers to communicate, educate and operate in an environment promoting
checks and balances. DMS is extremely unique and has been developed around the concept of promoting to patients the idea of becoming
proactive, rather than reactive with their healthcare and to follow the right side of State Law. In addition, it is our
desire to allow our clients to operate in an environment that will allow them to anticipate any changes to Federal and State Laws,
such as the likelihood of state required patient monitoring systems, akin to those currently required for the sale of other narcotics.
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS
OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION
The
accompanying condensed consolidated financial stateme
nts have been prepared by the Company without audit. In the opinion
of management, all adjustments necessary to present the financial position, results of operations and cash flows for the stated
periods have been made. Except as described below, these adjustments consist only of normal and recurring adjustments. Certain
information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with
accounting principles generally accepted in the United States of America have been condensed or omitted. These condensed financial
statements should be read in conjunction with a reading of the Company’s consolidated financial statements and notes thereto
included in the Company’s Form 10-K annual report filed with the Securities and Exchange Commission (SEC) on April 2, 2013.
Interim results of operations for the three and six months ended June 30, 2013 are not necessarily indicative of future results
for the full year. Certain amounts from the 2012 period have been reclassified to conform to the presentation used in the current
period.
The
condensed consolidated financial statements include the accounts of the Company and 800 Commerce, until May 10, 2012 when 800 Commerce
sold shares of its common stock to third parties resulting in the Company no longer holding a controlling interest in 800 Commerce.
All material intercompany balances and transactions have been eliminated
NONCONTROLLING INTEREST AND DECONSOLIDATION
On January 1, 2011, the Company
adopted authoritative accounting guidance that requires the ownership interests in subsidiaries held by parties other than the
parent, and income attributable to those parties, be clearly identified and distinguished in the parent’s consolidated financial
statements. The Company’s noncontrolling interest is now disclosed as a separate component of the Company’s consolidated
equity deficiency on the balance sheets. Earnings and other comprehensive income are separately attributed to both the controlling
and noncontrolling interests. Earnings per share are calculated based on net income attributable to the Company’s
controlling interest.
From January 1, 2011 through May 31,
2011, the Company owned 100% of 800 Commerce. From June 1, 2011 through October 1, 2011 800 Commerce sold 465,000 shares of its
common stock and issued 3,534,000 shares of its common stock to its officers as compensation. After these transactions, the Company
owned 60% of 800 Commerce. On May 10, 2012, 800 Commerce sold 3,150,000 shares of its common stock, reducing the Company’s
ownership to 45%. On May 18, 2012, 800 Commerce sold 1,500,000 shares of its common stock, reducing the Company’s ownership
to 40%. On June 10, 2012 issued 1,500,000 shares of common stock pursuant to a consulting agreement and 1,851,000 shares of common
stock for legal services and in lieu of compensation, and since June 30, 2012, 800 Commerce has sold 500,000 shares of its common
stock and issued 500,000 shares of its common stock pursuant to a consulting agreement. Subsequent to these issuances the Company
currently owns approximately 32% of the outstanding common stock of 800 Commerce. Effective May 10, 2012, the Company is no longer
consolidating 800 Commerce in its’ financial statements. The noncontrolling interest included in the Company’s consolidated
statement of operations is a result of noncontrolling interest investments in 800 Commerce up to the date of deconsolidation of
May 10, 2012. Noncontrolling interests through May 10, 2012 are classified in the condensed consolidated statements of operations
as part of consolidated net loss.
Subsequent to May 10, 2012, the Company’s
investment in 800 Commerce is accounted for using the equity method and was reduced to zero.
CASH AND CASH EQUIVALENTS
The Company considers all highly liquid
investments with an original term of three months or less to be cash equivalents.
ACCOUNTS RECEIVABLE
The Company records accounts receivable from
amounts due from its processors and customers. The records accounts receivable upon the shipment of products. The Company charges
certain merchants for processing services at a bundled rate based on a percentage of the dollar amount of each transaction and,
in some instances, additional fees are charged for each transaction. The Company charges other merchant customers a flat fee per
transaction, and may also charge miscellaneous fees to our customers, including fees for returns, monthly minimums, and other miscellaneous
services. All the charges and collections thereon flow through our processors who then remit the fee due the Company within the
month following the actual charges.
DEFERRED FINANCING COSTS
The costs related to the issuance of debt are
capitalized and amortized to interest expense using the straight-line method through the maturities of the related debt.
REVENUE RECOGNITION
The Company recognizes revenue in accordance
with FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria are met: (1) persuasive evidence of an arrangement
exists, (2) delivery of products and services has occurred, (3) the fee is fixed or determinable and (4) collectability is reasonably
assured.
The Company recognizes revenue during
the month in which products are shipped or commissions are earned.
FAIR VALUE OF FINANCIAL INSTRUMENTS
Fair value measurements are determined
under a three-level hierarchy for fair value measurements that prioritizes the inputs to valuation techniques used to measure fair
value, distinguishing between market participant assumptions developed based on market data obtained from sources independent of
the reporting entity (“observable inputs”) and the reporting entity’s own assumptions about market participant
assumptions developed based on the best information available in the circumstances (“unobservable inputs”).
Fair value is the price that would be
received to sell an asset or would be paid to transfer a liability (i.e., the “exit price”) in an orderly transaction
between market participants at the measurement date. In determining fair value, the Company primarily uses prices and other relevant
information generated by market transactions involving identical or comparable assets (“market approach”). The Company
also considers the impact of a significant decrease in volume and level of activity for an asset or liability when compared with
normal activity to identify transactions that are not orderly.
The highest priority is given to unadjusted
quoted prices in active markets for identical assets (Level 1 measurements) and the lowest priority to unobservable inputs (Level
3 measurements). Securities are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement.
The three hierarchy levels are defined
as follows:
Level 1 – Quoted
prices in active markets that is unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2 – Quoted
prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in
active markets or financial instruments for which significant inputs are observable, either directly or indirectly;
Level 3 – Prices
or valuations that require inputs that are both significant to the fair value measurement and unobservable.
Credit risk adjustments are applied to
reflect the Company’s own credit risk when valuing all liabilities measured at fair value. The methodology is consistent
with that applied in developing counterparty credit risk adjustments, but incorporates the Company’s own credit risk as observed
in the credit default swap market.
The Company's financial instruments
consist primarily of cash, accounts payable and accrued expenses, and convertible debt. The carrying amounts of such financial
instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest
rates of these instruments. The estimated fair value is not necessarily indicative of the amounts the Company would
realize in a current market exchange or from future earnings or cash flows.
INCOME TAXES
The Company accounts for income
taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated
future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related
to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized.
Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.
ASC 740-10 prescribes a recognition
threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on
recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues.
Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed,
nor paid, any interest or penalties.
Uncertain tax positions are measured
and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected
to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may
be recognized or continue to be recognized. The Company’s tax years subsequent to 2005 remain subject to examination by federal
and state tax jurisdictions.
EARNINGS (LOSS) PER SHARE
Earnings (loss) per share are computed
in accordance with ASC 260, "Earnings per Share". Basic earnings (loss) per share is computed by dividing net income
(loss), after deducting preferred stock dividends accumulated during the period, by the weighted-average number of shares of common
stock outstanding during each period. Diluted earnings per share is computed by dividing net income by the weighted-average number
of shares of common stock, common stock equivalents and other potentially dilutive securities, if any, outstanding during the period.
There were 3,000,000 outstanding warrants as of June 30, 2013. There were no outstanding warrants or options as of June 30, 2012.
As of June 30, 2013, the Company’s outstanding convertible debt is convertible into 5,667,304 shares of common stock and
1,000,000 shares of Class B convertible preferred stock is convertible into 222,728,359 shares of common stock. These amounts are
not included in the computation of dilutive loss per share because their impact is antidilutive.
ACCOUNTING FOR STOCK-BASED COMPENSATION
The Company accounts for stock awards
issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. The measurement date is the earlier
of (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the
date at which the counterparty's performance is complete. Stock awards granted to non-employees are valued at their respective
measurement dates based on the trading price of the Company’s common stock and recognized as expense during the period in
which services are provided.
For the three and six months ended June
30, 2013, the Company recorded stock and warrant based compensation of $3,116,681 and $3,221,015, respectively. For the three and
six months ended June 30, 2012, there was no stock based compensation expense (See Notes 7 and 8).
USE OF ESTIMATES
The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities
at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reported period.
Actual results could differ from those estimates.
NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS
Accounting standards that have been
issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected
to have a material impact on the consolidated financial statements upon adoption.
NOTE 4 - RECLASSIFICATIONS
Certain prior period balances have been
reclassified to conform to the current period's financial statement presentation. These reclassifications had no impact on previously
reported results of operations or stockholders' deficiency.
NOTE 5 – SALES CONCENTRATION AND CONCENTRATION OF CREDIT
RISK
Cash
Financial instruments that potentially subject the Company to concentrations
of credit risk consist principally of cash. The Company maintains cash balances at one financial institution,
which is insured by the Federal Deposit Insurance Corporation (“FDIC”). The FDIC insured institution insures
up to $250,000 on account balances. The company has not experienced any losses in such accounts.
Sales
For the six months ended June 30, 2103
three (3) customers each accounted for more than 10% of our business, as follows:
Customer
|
|
Sales %
|
|
Accounts
Receivable Balance
|
|
A
|
|
|
|
56.6
|
|
|
$
|
—
|
|
|
B
|
|
|
|
16.4
|
|
|
|
14,400
|
|
|
C
|
|
|
|
13.5
|
|
|
|
9,664
|
|
Purchases
For the three and six months ended June
30, 2013, 100% of our purchases were from one vendor related to the purchase of Chillo and C+ Swiss drinks.
NOTE 6 – CONVERTIBLE DEBT
In December
2011 the Company issued a $50,000 convertible promissory note as part of a guaranty fee due (the “Guaranty Note”) to
a Company that is affiliated with a former officer of the Company. Terms of the note included an eight percent per annum interest
rate and the note matured on the one year anniversary on December 20, 2012.
Additionally, the holder of the Note had the
right to convert the note into shares of common stock of the Company at a conversion price equal to eighty percent (80%) of the
lowest closing bid price of the common stock within five (5) days of the conversion. The beneficial conversion feature included
in the Guaranty Note resulted in an initial debt discount and derivative liability of $36,765.
During the year ended December 31, 2012,
the company made payments of $18,000, reducing the balance of the Guaranty Note to $32,000 as of December 31, 2012. As of December
31, 2012 the Company revalued the remaining conversion feature of the Guaranty Note at $13,209. On March 31, 2013 the Company and
the noteholder elected to convert the remaining $32,000 balance of the note and accrued and unpaid interest of $6,060 into 3,699,280
shares of common stock. The fair value of derivative liability on the date of conversion totaling $13,209 was reclassed to additional
paid in capital.
On November 28, 2012 the Company entered
into a $23,500 convertible note agreement (the 2012 Note) with Asher Enterprises, Inc. (“Asher”). We received net proceeds
of $20,000 from the 2012 Note after debt issuance costs of $2,500 paid for lender legal fees. These debt issuance costs will be
amortized over the earlier of the terms of the Note or any redemptions and accordingly $1,370 and $2,203 has been expensed as debt
issuance costs (included in interest expense) for the three and six months ended June 30, 2013.
The Company determined that the conversion
feature of the 2012 Note represents an embedded derivative since the Note is convertible into a variable number of shares upon
conversion. Accordingly, the Note is not considered to be conventional debt under EITF 00-19 and the embedded conversion feature
must be bifurcated from the debt host and accounted for as a derivative liability. Accordingly, the fair value of this derivative
instrument has been recorded as a liability on the consolidated balance sheet with the corresponding amount recorded as a discount
to each Note. Such discount will be amortized from the date of issuance to the maturity dates of the Note. The change in the fair
value of the liability for derivative contracts will be recorded in other income or expenses in the consolidated statements of
operations at the end of each quarter, with the offset to the derivative liability on the balance sheet. The beneficial conversion
feature included in the 2012 Note resulted in an initial debt discount of $23,500 and an initial loss on the valuation of derivative
liabilities of $1,826 for a derivative liability initial balance of $25,326.
As of December 31, 2012, the Company
revalued the embedded conversion feature of the November 2012 Note. For the period from November 28, 2012 through December 31,
2012, the Company increased the derivative liability of $25,326 by $55 resulting in a derivative liability balance of $25,381.
As of March 31, 2013 the Company revalued the embedded conversion feature of the November 2012 Note and for the period from December
31, 2012 to March 31, 2013, the Company decreased the derivative liability of the 2012 Note by $11 resulting in a derivative liability
balance of $25,370. During the quarter ended June 30, 2013, the Company issued 1,210,273 shares of common stock in satisfaction
of the convertible note and $940 of accrued and unpaid interest. The shares were issued at approximately $0.02 per share. The fair
value of derivative liability on the date of conversion totaling $25,382 was reclassed to additional paid in capital.
On January 2, 2013, February 11, 2013
and April 10, 2013, the Company entered convertible note agreements (the 2013 Notes) with Asher for $37,500, $27,500 and $27,500,
respectively. We received net proceeds of $85,000 from the 2013 Notes after debt issuance costs of $7,500 paid for lender legal
fees. These debt issuance costs will be amortized over the earlier of the terms of the Note or any redemptions and accordingly
$2,333 and $3,620 has been expensed as debt issuance costs (included in interest expense) for the three and six months ended June
30, 2013. The beneficial conversion feature included in the 2013 Notes resulted in an initial debt discount of $92,500 and an initial
loss on the valuation of derivative liabilities of $17,210 for a derivative liability initial balance of $109,710.
The fair value of the embedded conversion
features of the 2013 Notes was calculated at each issue date utilizing the following assumptions:
Issuance Date
|
|
Fair Value
|
|
Term
|
|
Assumed Conversion Price
|
|
Market Price on Grant Date
|
|
Expected
Volatility Percentage
|
|
Risk free
Interest
Rate
|
1/3/13
|
|
$
|
40,476
|
|
|
|
9 months
|
|
|
$
|
0.009
|
|
|
$
|
0.0179
|
|
|
|
158
|
%
|
|
|
0.12
|
%
|
2/11/13
|
|
|
29,761
|
|
|
|
9 months
|
|
|
$
|
0.0439
|
|
|
$
|
0.0884
|
|
|
|
172
|
%
|
|
|
0.11
|
%
|
4/10/13
|
|
|
39,473
|
|
|
|
9 months
|
|
|
$
|
0.0311
|
|
|
$
|
0.045
|
|
|
|
171
|
%
|
|
|
0.15
|
%
|
As of June 30, 2013 the Company revalued
the embedded conversion feature of the 2013 Notes. From their dates of issuance, the Company increased the derivative liability
of the 2013 Notes by $13,082 resulting in a derivative liability of $122,792. The fair value of the 2013 Notes was calculated at
June 30, 2013 utilizing the following assumptions:
Note
Issuance
Date
|
|
Fair Value
|
|
Term
|
|
Assumed Conversion Price
|
|
Expected
Volatility Percentage
|
|
Risk free
Interest Rate
|
1/3/13
|
|
$
|
50,335
|
|
|
|
3 months
|
|
|
$
|
0.0217
|
|
|
|
155
|
%
|
|
|
0.02
|
%
|
2/11/13
|
|
|
36,912
|
|
|
|
4 months
|
|
|
|
0.0217
|
|
|
|
155
|
%
|
|
|
0.06
|
%
|
4/18/13
|
|
|
35,545
|
|
|
|
6 months
|
|
|
|
0.0217
|
|
|
|
155
|
%
|
|
|
0.11
|
%
|
The inputs used to estimate the fair
value of the derivative liabilities are considered to be level 2 inputs within the fair value hierarchy.
A summary of the derivative liability
balance as of December 31, 2012 and June 30, 2013 is as follows:
Fair Value
|
|
Derivative
Liability Balance
12/31/12
|
|
Initial Derivative Liability
|
|
Redeemed
Convertible
Notes
|
|
Fair value change- six months ended 6/30/13
|
|
Derivative Liability Balance 6/30/13
|
Guaranty Note
|
|
$
|
13,209
|
|
|
|
—
|
|
|
$
|
(13,209
|
)
|
|
|
—
|
|
|
|
—
|
|
2012 Note
|
|
|
25,381
|
|
|
|
—
|
|
|
|
(25,381
|
)
|
|
|
—
|
|
|
|
—
|
|
2013 Notes
|
|
|
—
|
|
|
|
109,710
|
|
|
|
|
|
|
|
13,082
|
|
|
|
122,792
|
|
Total
|
|
$
|
38,590
|
|
|
$
|
109,710
|
*
|
|
$
|
(38,590
|
)
|
|
$
|
13,082
|
|
|
$
|
122,792
|
|
*Comprised of $92,500, the discount
on the face value of the convertible note and the initial derivative liability expense of $17,210 which is included in the derivative
liability expense of $30,293 on the condensed statement of operations for the six months ended June 30, 2013, included herein.
On May 20, 2013, the Company entered into a
Securities Purchase Agreement with Typenex Co-Investment, LLC ("Typenex"), for the sale of an 8% convertible note in
the principal amount of up to $667,500 (which includes Typenex legal expenses in the amount of $7,500 and a $60,000 original issue
discount) (the “Company Note”) for $600,000, consisting of $100,000 paid in cash at closing (May 21, 2013) and five
secured promissory notes, aggregating $500,000, bearing interest at the rate of 8% per annum. The first note was funded on June
13, 2013 and the four remaining notes each maturing sixty (60) days following the occurrence of the Maturity Date (the “Investor
Notes”). The Investor Notes may be prepaid, without penalty, all or portion of the outstanding balance along with accrued
but unpaid interest at any time prior to maturity. The Company has no obligation to pay Typenex any amounts on the unfunded portion
of the Note.
The Note bears interest at the rate of 8% per
annum. All interest and principal must be repaid on June 16, 2014. The Note is convertible into common stock, at Typenex’s
option, at a price of $0.055 per share. In the event the Company elects to prepay all or any portion of the Note, the Company is
required to pay to Typenex an amount in cash equal to 125% multiplied by the sum of all principal, interest and any other amounts
owing.
Typenex has agreed to restrict its ability
to convert the Note and receive shares of common stock such that the number of shares of common stock held by them in the aggregate
and their affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common
stock.
The Note is a debt obligation arising other than in the ordinary course
of business, which constitutes a direct financial obligation of the Company.
The Note also provides for penalties and rescission
rights if we do not deliver shares of our common stock upon conversion within the required timeframes.
The Company claims an exemption from the registration
requirements of the Securities Act of 1933, as amended (the “Act) for the private placement of these securities pursuant
to Section 4(2) of the Act and/or Regulation D promulgated there under since, among other things, the transaction did not involve
a public offering, Typenex is an accredited investor and had access to information about the Company and their investment, Typenex
took the securities for investment and not resale, and the Company took appropriate measures to restrict the transfer of the securities.
NOTE
7 – RELATED PARTY TRANSACTIONS
Management fees and stock compensation
expense
Effective January 1, 2011, the Company
has agreed to annual compensation of $90,000 for its CEO, which was increased to $150,000 annually, effective January 1, 2013.
Effective January 1, 2013, the Company has agreed to annual compensation of $96,000 for the CFO.
In August 2012, the Company issued
250,000 shares of Class B Preferred Stock to the President, valued at $177,667 and recorded the amount as deferred stock
compensation to be amortized over one year. As of June 30, 2013, the Company accepted the resignation of Mr. Rodriguez as an
Officer and Director of the Company. The Company has cancelled the Preferred Stock and returned the shares to the treasury of
the Company for failure to complete the employment agreement and the SweetMD transaction. Therefore, the Company stopped amortizing the
deferred compensation during the quarter ended June 30, 2013, and recorded an entry to eliminate the remaining unamortized
compensation of $29,611 with the corresponding entry to additional paid in capital. The company recognized expenses $37,014
and $81,431 for the three and six months ended June 30, 2013.
In June 2013, Mr. Friedman agree to
exchange 30,335,000 shares of common stock in partial consideration for the issuance of 450,000 shares of Class B preferred stock
(see note 8).
Agreements with prior management
In December
2011 the Company issued a $50,000 convertible promissory note (see Note 6) as part of a guaranty fee due to a Company that is affiliated
with a former officer of the Company. Terms of the note include an eight percent per annum interest rate and the note matured on
the one year anniversary on December 20, 2012.
Additionally, the holder of the Note has the right to convert the note into
shares of common stock of the Company at a conversion price equal to eighty percent (80%) of the lowest closing bid price of the
common stock within five (5) days of the conversion. On March 31, 2013, the Company and the noteholder elected to convert the remaining
balance of the note of $32,000 and accrued and unpaid interest of $6,060 into 3,699,280 shares of common stock.
Also in December 2011, the Company agreed
to pay an additional $50,000 in common stock, which is included in accounts payable and accrued expenses on the June 30, 2013 and
December 31, 2012 consolidated balance sheets.
NOTE 8 – COMMON AND PREFERRED
STOCK
Common Stock
On March 19, 2013, the Company issued
250,000 shares of restricted common stock, to Empire Relations Holdings, LLC, as consideration under a consulting agreement dated
March 7, 2013 for public and financial relations services. The fair value was $15,500 based on the closing stock price of $0.062
per share on the measurement date as the shares are non-refundable and no future performance obligation exists.
On March 31, 2013, the Company agreed
to issue 3,699,280 shares of common stock upon the conversion of the remaining balance of $32,000 of the guaranty note and accrued
and unpaid interest of $6,060 (see notes 6 and 7).
Previously the Company appointed Mr.
Jayme Canton to be an advisor to the Company’s Board of Directors. In April 2013, the Company agreed to issue to Mr. Canton
2,000,000 shares of common stock, a warrant to purchase 3,000,000 shares of common stock at an exercise price of $0.05 per share
with an expiration date on the third year anniversary of the grant, and 250,000 shares of common stock to be issued at the end
of each calendar quarter beginning on June 30, 2013 and ending on the earlier of March 31, 2015 (the term of Canton’s advisor
role) or the date Canton is no longer serving as an advisor to the board of directors. The Company included $9,775 in stock based
compensation expense for the shares issued as of June 30, 2013, based upon the market price of the common stock of $.0391 per share.
On April 23, 2013 the Company issued
a Convertible Note to an unaffiliated third party in exchange and for the cancellation of a litigation contingency of $46,449,
which was acquired by the third party. Also on April 23, 2013, the Company issued 1,750,000 shares of common stock in satisfaction
of the April 23, 2013 Convertible Note. The shares were issued at $0.0265 per share, and the Company recorded a beneficial conversion
feature expense of $29,561.
On June 26, 2013, B. Michael Friedman,
the Company’s CEO exchanged 30,335,000 shares of common stock for 450,000 shares of Class B Preferred Stock. The Company
reduced accrued compensation due Mr. Freidman of $100,022 and recognized stock based compensation expense of $2,821,275.
Preferred Stock
As of December 31, 2012, the Company had
800,000 shares of Series B Preferred Stock (the “Class B Preferred Stock”), par value $0.01 outstanding. On June 12,
2013, pursuant to Rodriguez’s resignation, non-execution of the employment agreement dated August 10, 2012 and the failure
to close the transaction between the Company and SweetMD, Inc., the Company cancelled the book entry of Rodriguez’s 250,000
shares of Class B Preferred Stock.
Subsequent to the issuance of 450,000
shares of Class B Preferred Stock as above, there are 1,000,000 shares of Class B Preferred Stock outstanding as of June 30, 2013.
The rights, preferences and restrictions
of the Class B Preferred Stock as amended, state; i)Each share of the Class B Convertible Preferred Stock shall automatically convert
(the “Conversion”) into shares of the Corporation’s common stock at the moment there are sufficient authorized
and unissued shares of common stock to allow for the Conversion. The Class B Convertible Preferred Stock will convert in their
entirety, simultaneously to equal one half (1/2) the amount of shares of common stock outstanding on a fully diluted basis immediately
prior to the Conversion. The Conversion shares will be issued pro rata so that each holder of the Class B Convertible Preferred
Stock will receive the appropriate number of shares of common stock equal to their percentage ownership of their Class B Convertible
Preferred Stock
and ii) all of the outstanding shares of the Class B Preferred Stock in their entirety
will have voting rights equal to the amount of shares of common stock outstanding on a fully diluted basis immediately prior to
any vote.
The shares eligible to vote will be calculated pro rata so that each holder of the Class B Convertible Preferred
Stock will be able to vote the appropriate number of shares of common stock equal to their percentage ownership of their Class
B Convertible Preferred Stock
. The Class B Convertible Preferred Stock shall have a right to vote on
all matters presented or submitted to the Corporation’s stockholders for approval in pari passu with holders of the Corporation’s
common stock, and not as a separate class.
Warrants
On April 26, 2013 and in connection
with the appointment of Mr. Jayme Canton to the Company’s advisory board, the Company issued a warrant to Mr. Canton to purchase
3,000,000 shares of common stock. The warrant expires on the three year anniversary and has an exercise price of $0.05 per share.
The Company valued the warrant at $124,200 based on the Black Scholes formula and the following assumptions:
Estimated market value of common stock on measurement date: $0.04
Exercise price: $0.05
Risk free interest rate: 11%
Term in years: 3 years
Expected volatility: 223%
Expected dividends: 0.00%
A summary of the activity of the
Company’s outstanding warrants at January 1, 2013 and June 30, 2013 is as follows:
|
|
Warrants
|
|
Weighted-average exercise price
|
|
Weighted-average grant date fair value
|
Outstanding and exercisable at January 1, 2013
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Granted
|
|
|
3,000,000
|
|
|
|
0.05
|
|
|
|
0.0414
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding and exercisable at June 30, 2013
|
|
|
3,000,000
|
|
|
$
|
0.05
|
|
|
$
|
0.0414
|
|
NOTE 9 – INCOME TAXES
Deferred income taxes reflect the net
tax effects of operating loss and tax credit carry forwards and temporary differences between carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets,
management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in
which temporary differences representing net future deductible amounts become deductible. Due to the uncertainty of the Company’s
ability to realize the benefit of the deferred tax assets, the deferred tax assets are fully offset by a valuation allowance at
June 30, 2013 and 2012.
As of June 30, 2013, the Company had
a tax net operating loss carry forward of approximately $720,000.
Any unused portion of this carry
forward expires in 2030. Utilization of this loss may be limited in the event of an ownership change pursuant to IRS Section 382.
NOTE 10 – CONTINGENCIES AND COMMITMENTS
Effective on April 1, 2013, the Company
entered into a three year agreement to rent office space in Detroit, Michigan. Totaling approximately 2,500 square feet, the space
will also be used to operate the Company’s Certification Station business. The Company’s monthly rent is $2,200.
The Company is not aware of any legal
proceedings against it as of June 30, 2013. No contingencies have been provided in the financial statements.
NOTE 11 – GOING CONCERN
The accompanying consolidated financial
statements have been prepared assuming the Company will continue as a going concern. As of June 30, 2013, the Company had an accumulated
deficit of $8,497,423 and a working capital deficit of $340,957. These conditions raise substantial doubt about the Company's ability
to continue as a going concern.
The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.
NOTE 12
–
SEGMENT
REPORTING
Description of segments
During the six months ended
June 30, 2013, the Company had operated in two reportable segments: accounts receivable financing and wholesale sales. Prior to
April 1, 2013, the Company was receiving fees as the agent of record for fees pursuant to the ACS agreement. Beginning in the
quarter ended June 30, 2013, the Company began wholesaling products (Chillo drinks). The accounting policies of the segments are
the same as those described in the Note 1. The Company’s reportable segments are strategic business units that offer
products.
For the six months ended June 30, 2013, segment results are as follows:
|
|
|
Processing
fees
|
|
|
|
Wholesale
|
|
|
|
Corporate
|
|
|
|
Total
|
|
Net revenues
|
|
$
|
49,818
|
|
|
$
|
38,267
|
|
|
$
|
—
|
|
|
$
|
88,085
|
|
Cost of sales
|
|
|
—
|
|
|
|
24,369
|
|
|
|
—
|
|
|
|
24,369
|
|
Operating costs
|
|
|
47,900
|
|
|
|
9,714
|
|
|
|
232,371
|
|
|
|
289,985
|
|
Other non-cash items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation
|
|
|
—
|
|
|
|
—
|
|
|
|
3,221,015
|
|
|
|
3,221,015
|
|
Other expense
|
|
|
—
|
|
|
|
—
|
|
|
|
152,853
|
|
|
|
152,853
|
|
Segment gain or ( loss)
|
|
|
1,918
|
|
|
|
4,184
|
|
|
|
(3,606,239
|
)
|
|
|
(3,600,137
|
)
|
Segment assets
|
|
|
—
|
|
|
|
42,837
|
|
|
|
141,724
|
|
|
|
184,561
|
|
NOTE 13 – SUBSEQUENT EVENTS
On August 5, 2013, 800 Commerce filed
Amendment No.5 to its’ S-1 Registration Statement with the Securities and Exchange Commission (“SEC”). Upon approval
from the SEC and other regulatory approvals required, the Company will announce a shareholder record date, whereby shareholders
of the Company as of that date will be entitled to their pro-rata share of the six million shares of 800 Commerce common stock
owned by the Company. The SEC declared the registration statement effective on August 8, 2103.
On July 8, 2013, the Company issued
1,857,143 shares of common stock in satisfaction of the January 2, 2013 Asher convertible note of $37,500 and accrued and unpaid
interest of $1,500. The shares were issued at $0.021 per share.
On July 22, 2013, the Company issued
a convertible promissory note to Asher for $65,000 under the same terms of the 2013 Notes described in Note 6. The note was funded
by Asher on July 29, 2013.
On August 1, 2013, the Company and Medical
Cannabis Network, Inc. (“MCN”) entered into a Subscription and Services Agreement (the “SSA”). Pursuant
to the terms of the SAA, the Company has the exclusive license to access and use MCN’s products and services, included but
not limited to, technology (services collaboration software) and services (including hosting, professional services support and
maintenance). The six month exclusive license requires the Company to pay MCN $3,000 per month for the first two months of the
agreement and $5,000 per month thereafter.
The Company Management performed an
evaluation of the Company’s activity through the date these financials were issued to determine if they must be reported.
The Management of the Company determined that there were no other reportable subsequent events to be disclosed.
ITEM 2. MANAGEMENT'S DISCUSSION
AND ANALYSIS OR PLAN OF OPERATION
The following is management’s
discussion and analysis of certain significant factors that have affected our financial position and operating results during the
periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current
management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,”
“may,” “will,” “should,” “expect,” “intend,” “estimate,”
“continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking
statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other
reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or
outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which
speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.
The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with the audited consolidated financial statements
and notes thereto for the years ended December 31, 2012 and 2011, included in our annual report on Form 10-K filed with the SEC
on April 13, 2013.
The independent auditors reports on
our financial statements for the years ended December 31, 2012 and 2011 includes a “going concern” explanatory paragraph
that describes substantial doubt about our ability to continue as a going concern. Management’s plans in regard to the factors
prompting the explanatory paragraph are discussed below and also in Note 11 to the condensed consolidated financial statements
filed herein.
(a)
Liquidity and Capital Resources.
For the six months ended June 30, 2013,
net cash used in operating activities was $151,505 compared to $29,577 for the six months ended June 30, 2012. The company had
a net loss $3,600,137 for the six months ended June 30, 2013 compared to a net loss of $83,529 for the six months ended June 30,
2012. The net loss for the six months ended June 30, 2013 was impacted by stock and warrant compensation expense of $3,221,015
comprised of $2,821,275 of preferred stock compensation, the amortization of deferred stock compensation of $170,265 from the previous
issuance of Series B preferred stock, $124,200 warrant based compensation for the issuance of a warrant to purchase 3,000,000 shares
of common stock to our advisor to the board of directors, $80,000 for the one time issuance of 2,000,000 shares of common stock
to the same advisor, 250,000 shares of common stock (with an additional 250,000 shares to be issued each quarter the advisor continues
his relationship with the Company) valued at $9,775 and $15,500 for the issuance of 250,000 shares for services provided to the
Company. Additional non-cash expenses for the six months ended June 30, 2013 were the amortization of the initial discounts of
$61,998 on the convertible notes, the initial derivative liability expense and the change in the fair value of the derivatives
of $30,293, amortization of deferred financing fees of $13,916 also related to the convertible promissory notes and a beneficial
conversion feature related to the conversion of the contingent liability to common stock of $29,561.
During the six months ended June 30,
2013, net cash provided by financing activity was $266,500. This was comprised of issuance of convertible promissory notes of $92,500,
proceeds of $200,000 related to the Typenex convertible note (see note 6 to the condensed consolidated financial statements contained
herein) and the payment of deferred financing fees of $26,000.
For the six months ended June 30, 2013,
cash and cash equivalents increased by $114,995 compared to a decrease of $2,577 for the six months ended June 30, 2012. Ending
cash and cash equivalents at June 30, 2013 was $116,887 compared to $1,892 at December 31, 2012.
We have limited cash and cash equivalents
on hand.
We presently maintain our daily operations and capital needs through the sale of our products.
We will need to raise funds to continue to be able to support our operating expenses and to meet our other obligations
as they become due. Sources available to us that we may utilize include the sale of unsecured convertible debentures from unaffiliated
investors which may cause dilution to our stockholders.
The company expects to increase sales of additional
products over the course of this fiscal year.
(b)
Results of Operations
Results of operations for the three and six months ended
June 30, 2013 vs. June 30, 2012
REVENUES
During the three and six
months ended June 30, 2013, the Company’s revenues were $38,267 and $88,065, respectively, compared to $23,334 and
$49,458 for the three and six months ended June 30, 2012, respectively. The revenues for the six months ended June 30, 2013,
were comprised of $49,818 from Alternative Capital Solutions (“ACS”), $30,354 from our sales of our Chillo and C+
Swiss products and $7,914 related to our Cloud based products. In April 2013, ACS and the Company terminated their agreements
and accordingly, the Company will no longer be receiving fees related to the ACS agreement. The Company recently entered into
an exclusive distributorship agreement with Chill Drinks, LLC (See Note 1) for sales of Chill Drink’s products to
dispensaries. Sales began in April 2013. Also during the quarter ending June 30, 2013 the Company generated revenues related
to its’ patient software (See note 1) and anticipates to begin a monthly recurring revenue model, whereby dispensaries
will pay up to $400 per month for access to Cloud based software. Additionally through Cloud based software, the Company will be
selling a patient digital health record storage system for an annual fee. The Company will be introducing additional products
in the forthcoming quarters to supplement the initial products.
Revenues from 2012 period were all
related to merchant processing fees the Company received from medical dispensaries. Effective July 1, 2012, the merchant processing
fees ceased as a result of Mastercard and Visa declining to accept credit card charges from medical dispensaries.
OPERATING EXPENSES
Operating expenses were $3,247,517 and
$3,511,000 for the three and six months ended June 30, 2013, compared to $67,104 and $121,426 for the three and six months ended
June 30, 2012. The expenses were comprised of:
|
|
2013
|
|
2012
|
Description
|
|
Three months ended June 30
|
|
Six months ended June 30
|
|
Three months ended June 30
|
|
Six months ended June 30
|
Administration and management fees
|
|
$
|
69,680
|
|
|
$
|
135,180
|
|
|
$
|
34,888
|
|
|
$
|
60,788
|
|
Stock compensation expense, management
|
|
|
2,990,833
|
|
|
|
3,035,250
|
|
|
|
—
|
|
|
|
—
|
|
Stock compensation expense, other
|
|
|
125,848
|
|
|
|
185,765
|
|
|
|
—
|
|
|
|
—
|
|
Professional and consulting fees
|
|
|
19,869
|
|
|
|
48,871
|
|
|
|
5,050
|
|
|
|
7,400
|
|
Commissions
|
|
|
—
|
|
|
|
31,200
|
|
|
|
—
|
|
|
|
8,512
|
|
Advertising and promotional expenses
|
|
|
5,227
|
|
|
|
8,871
|
|
|
|
—
|
|
|
|
—
|
|
Rent and occupancy costs
|
|
|
15,031
|
|
|
|
18,783
|
|
|
|
5,957
|
|
|
|
11,683
|
|
General and other administrative
|
|
|
21,029
|
|
|
|
47,080
|
|
|
|
21,209
|
|
|
|
33,043
|
|
Total
|
|
$
|
3,247,517
|
|
|
$
|
3,511,000
|
|
|
$
|
67,104
|
|
|
$
|
121,426
|
|
Administration
and management fees increased as a result of the increase of the amount accrued for the salaries for our CEO from $22,500 for
the three and six months ended June 30, 2012 to $37,500 and $75,000 for the three and six months ended June 30, 2013, compensation
recorded for our CFO of $24,000 and $48,000 for the three and six months ended June 30, 2013.
Stock
compensation expense, management was comprised of $2,821,275 of preferred stock compensation, $124,200 warrant based compensation
for the issuance of a warrant to purchase 3,000,000 shares of common stock to our advisor to the board of directors, $80,000 for
the one time issuance of 2,000,000 shares of common stock to the same advisor, 250,000 shares of common stock (with an additional
250,000 shares to be issued each quarter the advisor continues his relationship with the Company) valued at $9,775. Stock compensation
expense, other includes the amortization of deferred stock compensation of $170,265 from the previous issuance of Series B preferred
stock and $15,500 for the issuance of 250,000 shares for services provided to the Company.
Professional and consulting fees increased
for the three and six month periods in 2013 compared to 2012 as a result of investor relation costs of $8,094 and $22,396 for the
three and six months ended June 30, 2013, respectively, compared to $2,650 and $6,200 for the three and six months ended June 30,
2012, respectively. Consulting fees of $4,500 and $19,200 were incurred for the three nd six months ended June 30, 2013, respectively
of which $16,700 was pursuant to the ACS agreement. Commissions of $31,200 were also incurred for the six months ended June 30,
2013pursuant to the ACS Agreement.
General and other administrative costs
for the three and six months ended June 30, 2013, were $21,029 and $47,080, respectively, compared to $21,029 and $33,043 for the
three and six months ended June 30, 2012, respectively. Expenses for the six months ended June 30, 2013, include public company
filing fees of $14,141, travel and entertainment costs of $11,547, internet and web based service costs of $8,386, certification
station set up costs of $2,904 and $10,102 of other general and administrative costs.
OTHER INCOME (EXPENSE)
Other expense for the three and six
months ended June 30, 2013 was $117,830 and $152,853, respectively, compared to $10,844 and $12,256 for the three and six months
ended June 30, 2012. Included in the current period is interest expense of $63,069 (three months) and $92,999 (six months), comprised
of $36,674 (three months) and $61,998 (six months) related to the amortization of the initial discount on convertible promissory
notes, $14,685 (three months) and $16,085 (six months) for the amortization of the deferred financing costs and $11,710 (three
months) and $14,196 (six months) for the interest expense on the face value of the notes. Also included in other expenses for the
six months ended June 30, 2013 was $17,210 for the initial derivative liability expense for the embedded derivative in newly issued
convertible notes and an expense of $13,083 for the fair value change on the derivative liability associated with the convertible
promissory notes. Other expenses for the three and six months ended June 30, 2012 included interest expense of $46,812 (three months
and $92,936 (six months). Interest expense was comprised of $41,477 (three months) and $81,806 (six months) related to the amortization
of the initial discount on convertible promissory notes, $2,719 (three months) and $5,526 (six months) for the amortization of
the deferred financing costs and $2,596 (three months) and $5,584 (six months) for the interest expense on the face value of the
notes. For the three months ended June 30, 2012 the fair value change in the derivative associated with convertible promissory
notes resulted in an expense of $26,668 and for the six months ended June 30, 2012, expenses were partially offset for the fair
value change (decrease) of $18,044 in the derivative liability associated with convertible promissory notes.
OFF BALANCE SHEET ARRANGEMENTS
None
Critical Accounting Policies
See Note 2 to the condensed consolidated financial statements
included herein.